Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C4 Therapeutics, Inc.

https://c4therapeutics.com/

Latest From C4 Therapeutics, Inc.

Finance Watch: Clouds Still Darken Biopharma Sector Despite Sunny Forecasts

Restructuring Edition: The industry emerged from the J.P. Morgan Healthcare Conference feeling renewed confidence about deal-making and financing, but drug developers continue to run short on cash or cut programs and jobs before the money runs out, including Cara, PMV and Ikena.

Financing Restructuring

Stock Watch: Too Early To Call The End Of Biotech Wilderness

To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.

Stock Watch Commercial

Merck’s Focus On ADCs Expands To Include Protein Degraders With C4

Deal snapshot: Viewing antibody-drug conjugates as a key to growing its cancer franchise beyond Keytruda, Merck & Co. will partner with C4 to develop protein degrader-antibody conjugates for cancer.

Deals Business Strategies

Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis

Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register